News | April 06, 2009

Lantheus Acquires Rights to MRA Contrast Agent for Peripheral Vascular Imaging

April 7, 2009 - Lantheus Medical Imaging Inc. has acquired the U.S., Canadian and Australian rights to MS-325 (formerly marketed as VASOVIST, gadofosveset trisodium, by Bayer Schering Pharma) from EPIX Pharmaceuticals.

In December 2008, EPIX received FDA marketing approval for the magnetic resonance angiography (MRA) agent MS-325 to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease. Currently, there are no other imaging agents approved for MRA in the U.S.

Under the terms of the agreement, Lantheus acquired the U.S. (including Puerto Rico), Canadian, and Australian rights to MS-325 from EPIX. EPIX will continue to own European and other ex-U.S. rights for the imaging agent. Lantheus is planning to launch MS-325 under a different name before the year-end.

MS-325 is an injectable intravascular contrast agent designed to provide improved imaging of the vascular system through MRA. MS-325 has been approved for marketing in the U.S. and in 37 countries outside the U.S.

For more information: www.lantheus.com.

Related Content

Jackson Memorial Hospital Holds Ribbon-cutting for New Cardiac Catheterization Labs
News | Angiography | August 21, 2019
Jackson Memorial Hospital in Miami celebrated the opening of two newly renovated cardiac catheterization suites during...
Videos | CT Angiography (CTA) | August 07, 2019
This is a quick walk around of the new Siemens Somatom Go.top cardiovascular edition compact computed tomography (CT)
Videos | CT Angiography (CTA) | August 07, 2019
This is a quick walk around of the GE Healthcare Cardiographe dedicated cardiac CT system on display at the...
Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing
News | Cardiovascular Ultrasound | August 07, 2019
Heart failure is the fourth most common cause for all admission to U.S. hospitals, and it is the most common reason for...
Artificial Intelligence Improves Heart Attack Risk Assessment
News | CT Angiography (CTA) | August 06, 2019
When used with a common heart scan, machine learning, a type of artificial intelligence (AI), does better than...
An example of FFR-CT imaging from Beaumont Hospital in Royal Oak, Mich. The left image shows a 3D generated image of the coronary tree from a CT scan evaluated with computational fluid dynamics to determine the FFR numbers. It shows a severe restriction of the left main artery which requires a stent to revacularize. The image on the right is a comparison with the invasive angiogram from the cath lab prior to stenting.

An example of FFR-CT imaging from Beaumont Hospital in Royal Oak, Mich. The left image shows a 3D generated image of the coronary tree from a CT scan evaluated with computational fluid dynamics to determine the FFR numbers. It shows a severe restriction of the left main artery which requires a stent to revacularize. The image on the right is a comparison with the invasive angiogram from the cath lab prior to stenting. 

Feature | Cardiac Imaging | July 24, 2019 | Greg Freiherr
One of the big trends in cardiac computed tomography (CT) imaging has been the introduction of noninvasive...